Previous 10 | Next 10 |
Image source: The Motley Fool. Reata Pharmaceuticals, Inc. (NASDAQ: RETA) Q3 2019 Earnings Call Nov 12, 2019 , 8:00 a.m. ET Operator Continue reading
Reata Pharmaceuticals (RETA) Positive Topline Pivotal Year 1 CARDINAL Data Call November 12, 2019 08:00 ET Company Participants Vinny Jindal - Vice President, Strategy Warren Huff - Chief Executive Officer Colin Meyer - Chief Medical Officer Manmeet Soni - Chief Financial Offic...
Yesterday, Reata Pharmaceuticals ( RETA ) reported the first topline results from its CARDINAL Phase 3 Bardoxolone trial . This is a trial for the use of Bardoxolone on Alport Syndrome. Alport is one of many genetic and environmental conditions leading to ESRD (End-Stage Renal Disease) requir...
PLANO, Texas, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced its intention to offer and sell 2,000,000 shares of its Class A common stock in an u...
RETA stock has soared over 155% over the past month on multiple news from Reata Pharmaceuticals Inc (NASDAQ:RETA). Many pharmaceutical stocks have enjoyed significant gains this year, but there are very few stocks that have made the sort of gains that were made by Reata Pharmaceuticals ...
Reata Pharmaceuticals (NASDAQ: RETA ): Q3 GAAP EPS of -$1.32 misses by $0.08 . More news on: Reata Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
PLANO, Texas, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2019, and provided an up...
Shares of biopharma company Reata Pharmaceuticals (NASDAQ: RETA) climbed 156.7% in October, according to data from S&P Global Market Intelligence . Shares had been stagnant since January. Reata's big month came in three stages. First, shares increased by a modest 13...
Gainers: BREW +122.2% . KDMN +18.1% . ICUI +11.1% . APYX +6.8% . GO +6.6% . More news on: Craft Brew Alliance, Inc., Kadmon Holdings, Inc., ICU Medical, Inc., Stocks on the move, Read more ...
Reata Pharmaceuticals (NASDAQ: RETA ) announces positive results from the Phase 3 part of its Phase 2/3 clinical trial, CARDINAL , evaluating bardoxolone methyl in patients with chronic kidney disease (CKD) caused by a rare inherited disorder called Alport syndrome . More news on: Reat...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...